Related Experiment Video
Updated: Jul 16, 2026
07:34
Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization
Published on: November 17, 2023
Howard A. "Skip" Burris III, MD: an oncology pioneer reflects on patients, progress, and purpose
The American Journal of Managed Care
|February 23, 2026
Abstract:
The originator of the phase 1 drug development program at Sarah Cannon Research Institute reflects on his career.
Insights
This reflection details the career of the founder of the phase 1 drug development program at Sarah Cannon Research Institute. It highlights key experiences in early-phase clinical trials and drug discovery.
Area of Science:
- Oncology
- Clinical Pharmacology
- Drug Development
Background:
- The landscape of early-phase clinical trials has evolved significantly.
- Pioneering drug development programs requires strategic vision and perseverance.
- Academic and community-based research institutes play a crucial role in advancing cancer therapies.
Purpose of the Study:
- To provide a personal reflection on the establishment and growth of a phase 1 drug development program.
- To share insights gained from a career dedicated to early-phase oncology research.
- To offer a historical perspective on the challenges and successes in bringing novel cancer drugs to patients.
Main Methods:
- Retrospective career review.
- Personal narrative and reflection.
- Analysis of historical program development milestones.
Main Results:
- Successful establishment and sustained growth of a leading phase 1 drug development program.
- Contribution to the advancement of multiple novel oncology therapeutics.
- Development of a robust framework for early-phase clinical trial execution.
Conclusions:
- The journey of establishing a phase 1 program is complex but rewarding.
- Sustained commitment to innovation is vital for progress in oncology drug development.
- Mentorship and collaboration are key to long-term success in clinical research.
Related Concept Videos
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:13Patient-centered Care
Patient-centered care involves delivering care beyond inpatient hospitalization. Reflective practice can enhance a patient-centered approach. Reflective practice is a process of reasoning that considers all aspects of the present situation, including practicalities, learning from personal practice, and consideration of patient needs. Patients appreciate care decisions made while considering their input. Involving the patient in their care provides the patient with a sense of contribution rather...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...